KALA BIO Inc（KALA）の株式分析KALAKALA BIO Inc

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

KALA BIO Inc is not a good buy right now due to its extremely low current price of 0.69, a year-to-date change of -97.78%, and a very low RSI of 19.193 indicating oversold conditions. The company has also announced a 1-for-50 reverse stock split, which has not improved market sentiment as the stock fell over 27% post-announcement. Furthermore, insider selling has increased by 177.30%, indicating a lack of confidence from those closest to the company. The main risk is the company's inability to maintain compliance with Nasdaq's minimum price requirement, as it must regain a price above $1 by July 20, 2026.

4 analysts cover KALA: 4 rate it Buy, 0 Hold and 0 Sell.